Abstract
Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients. Weight loss was similar in both groups: -2.8+/-3.2 kg vs. -1.4+/-2.6 kg. Except for preventing a triglyceride increase, the drug combination lacked efficacy for metabolic control in this clinical population.
Publication types
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antipsychotic Agents / adverse effects*
-
Antipsychotic Agents / therapeutic use
-
Appetite Depressants / therapeutic use*
-
Benzodiazepines / adverse effects*
-
Benzodiazepines / therapeutic use
-
Body Mass Index
-
Chronic Disease
-
Cyclobutanes / therapeutic use*
-
Double-Blind Method
-
Female
-
Humans
-
Hypoglycemic Agents / therapeutic use*
-
Male
-
Metabolic Syndrome / chemically induced*
-
Metabolic Syndrome / drug therapy*
-
Metformin / therapeutic use*
-
Middle Aged
-
Obesity / chemically induced*
-
Obesity / drug therapy*
-
Olanzapine
-
Pilot Projects
-
Placebos
-
Schizophrenia / diagnosis
-
Schizophrenia / drug therapy*
-
Schizophrenic Psychology
-
Waist-Hip Ratio
-
Weight Gain / drug effects
-
Weight Loss / drug effects
Substances
-
Antipsychotic Agents
-
Appetite Depressants
-
Cyclobutanes
-
Hypoglycemic Agents
-
Placebos
-
Benzodiazepines
-
Metformin
-
Olanzapine
-
sibutramine